Advances in LLM: Ponatinib: Targeting the T315i mutation in chronic myelogenous leukemia

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 12, 2011, Pages 925-926

  Shah, Neil P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BRC ABL GENE; CANCER CONTROL; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HEADACHE; HUMAN; MOLECULARLY TARGETED THERAPY; MUSCLE SPASM; MYALGIA; NAUSEA; NOTE; ONCOGENE; OUTCOME ASSESSMENT; PANCREATITIS; PROTEIN SYNTHESIS INHIBITION; RASH; SIDE EFFECT; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICAL RESEARCH; MUTATION; PHASE 1 CLINICAL TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS, PHASE I AS TOPIC; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; MUTATION; PYRIDAZINES;

EID: 84855798616     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Cortes J, Talpaz M, Bixby D, et al. A phase I trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract 210.
2. Talpaz M, Shah NP, Deininger MW, et al. Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies. J Clin Oncol (ASCO Annual Meeting Abstracts). 2011;29: Abstract 6518.
3. Cortes J, Dong-Wook K, Pinilla-Ibarz J, et al. Initial findings from the PACE trial: a pivotal phase II study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Blood (ASH Annual Meeting Abstracts). 2011;118: Abstract 109.